Arcutis Biotherapeutics, Inc.
ARQTReported to SECin USCIK 0001787306Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 45. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Matsuda MasaruSee Remarks | Open-market sell | $91,8533,674 shares | Sep 18, 2026 | Matsuda MasaruSee Remarks | $91,853 | Open-market sell | 3,674 | Sep 18, 2026 |
| Welgus Howard G.— | Option exercise | nothing paid2,255 shares | Sep 17, 2026 | Welgus Howard G. | nothing paid | Option exercise | 2,255 | Sep 17, 2026 |
| Welgus Howard G.— | Option exercise | nothing paid1,019 shares | Sep 17, 2026 | Welgus Howard G. | nothing paid | Option exercise | 1,019 | Sep 17, 2026 |
| Welgus Howard G.— | Option exercise | nothing paid822 shares | Sep 17, 2026 | Welgus Howard G. | nothing paid | Option exercise | 822 | Sep 17, 2026 |
| Welgus Howard G.— | Open-market sell | $114,3714,730 shares | Sep 17, 2026 | Welgus Howard G. | $114,371 | Open-market sell | 4,730 | Sep 17, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and Arcutis Biotherapeutics, Inc. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.